Document Detail


Guidelines and performance measures for the management of acute coronary syndrome.
MedLine Citation:
PMID:  18699707     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: Acute coronary syndrome (ACS) is caused by reduced perfusion of the myocardium and characterized by chest pain. The primary goals of treatment for ACS are to restore blood flow through occluded coronary arteries and prevent recurrent coronary events. Antiplatelet and anticoagulant therapies play a crucial role in the treatment of ACS by interrupting the thrombotic process. OBJECTIVES: To characterize the pathophysiology of ACS and to describe the American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for reperfusion therapy in patients with ST-segment elevation myocardial infarction (STEMI); the use of antiplatelet and anticoagulant therapies for the treatment of STEMI, non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina (UA), including patients who undergo percutaneous coronary intervention (PCI); and long-term antiplatelet therapy after an ACS episode. SUMMARY: The preferred reperfusion strategy in patients with STEMI is PCI if it can be performed within 90 minutes after arrival at the hospital. Patients with NSTEMI or UA also may undergo PCI. Thrombolysis is an alternative method of reperfusion for patients with STEMI but not for patients with NSTEMI or UA. Dual antiplatelet therapy with aspirin and the thienopyridine clopidogrel is recommended by the ACC/AHA for 12 months in patients with STEMI, NSTEMI, or UA, including patients with coronary stents. Platelet glycoprotein (GP) IIb/IIIa inhibitors are routinely used during PCI in patients with STEMI and NSTEMI. These agents should be used in addition to aspirin and clopidogrel in patients with NSTEMI and elevated troponin levels who undergo coronary intervention. Unfractionated heparin (UFH) or the low-molecular-weight heparin enoxaparin may be used in patients with STEMI undergoing reperfusion with thrombolytic agents or PCI and patients with NSTEMI or UA. There are substantial data on enoxaparin in the ACS arena, but UFH is preferred for patients who undergo coronary intervention because of greater ease of therapeutic monitoring and reversal of anticoagulant effects if bleeding complications arise. The pentasaccharide fondaparinux may become an alternative to UFH and enoxaparin for patients with STEMI and some patients with NSTEMI or UA. Fondaparinux is preferred for patients with NSTEMI or UA who are at increased risk for bleeding when a conservative approach is chosen, but it is not recommended for patients when an early invasive approach is chosen because of the risk of catheter-related thrombi. The direct thrombin inhibitor bivalirudin may be used for anticoagulation in patients with NSTEMI who undergo early invasive procedures, and GP IIb/IIIa inhibitor use may be avoided in some patients; however, upstream antiplatelet therapy with clopidogrel is also needed if these patients undergo PCI. Patients undergoing coronary stenting must receive dual antiplatelet therapy. CONCLUSIONS: Antiplatelet and anticoagulant therapies for patients with ACS are complex. Evidence-based guidelines facilitate the therapeutic decision-making process for these therapies in patients with ACS.
Authors:
Piotr Sobieszczyk
Related Documents :
11727277 - Intravenous glycoprotein iib/iiia inhibition in non-st segment elevation acute coronary...
15355747 - Aspirin, nsaids, and cox-2 inhibitors in cardiovascular disease: possible interactions ...
9779027 - Approaches to the treatment of unstable angina and non-q wave myocardial infarction.
1987387 - Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial.
19081647 - Incident coronary revascularization and subsequent mortality in chronic heart failure: ...
10639267 - Early, complete infarct vessel patency: arriving at a gold standard for future clinical...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of managed care pharmacy : JMCP     Volume:  14     ISSN:  1083-4087     ISO Abbreviation:  -     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-08-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9605854     Medline TA:  J Manag Care Pharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  4-13     Citation Subset:  IM    
Affiliation:
Cardiac Catheterization Laboratory, Brigham and Women's Hospital, Cardiovascular Division, 75 Francis St., Boston, MA 02115, USA. psobieszczyk@partners.org.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A simple probabilistic estimation of spray drift--factors determining spray drift and development of...
Next Document:  Guidelines and performance measures for the prevention and treatment of venous thromboembolism.